A Phase II Study of the Central European Society of Anticancer-Drug Research (CESAR) Group: Results of an Open-Label Study of Gemcitabine plus Cisplatin with or without Concomitant or Sequential Gefitinib in Patients with Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

Publisher： Karger

E-ISSN： 1423-0399|96|1|5-13

ISSN： 0042-1138

Source： Urologia Internationalis, Vol.96, Iss.1, 2016-0, pp. : 5-13

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Central European Society for Anticancer Drug Research (CESAR)

By  

Oncology Research and Treatment, Vol. 23, Iss. 5, 2000-11 ,pp. : 492-493

Karger

Access to resources Recommend Favorite

A Multicenter Phase II Study of Docetaxel in Combination with Gefitinib in Gemcitabine-Pretreated Patients with Advanced/Metastatic Pancreatic Cancer

By  

Oncology, Vol. 71, Iss. 3-4, 2007-07 ,pp. : 159-163

Karger

Access to resources Recommend Favorite

Phase II Study of Cisplatin Combined with Weekly Gemcitabine in the Treatment of Patients with Metastatic Pancreatic Carcinoma

By  

Pancreatology, Vol. 6, Iss. 6, 2007-03 ,pp. : 635-641

Karger

Access to resources Recommend Favorite

Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE)

By  

Oncology Research and Treatment, Vol. 39, Iss. 9, 2016-08 ,pp. : 539-547

Karger

Access to resources Recommend Favorite

Sequential erlotinib with gemcitabine in NSCLC

By  

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 11, Iss. 1, 2015-03 ,pp. : 4-14

John Wiley & Sons Inc

Access to resources Recommend Favorite